Amphastar Pharmaceuticals, Inc.(AMPH)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,598 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
AMPH Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Amphastar Pharmaceuticals, Inc. (AMPH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMPH at 50.5/100 on a 32-signal composite quality model, placing it at rank #1,598 of 2,962 stocks — the bottom half of the AI-ranked universe. AMPH scores in the top quartile across earnings quality (86.0). Areas of concern include institutional flow (4.5) and revenue growth (36.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Amphastar Pharmaceuticals, Inc. reports quarterly revenue of $183.9M, net income of $30.3M, free cash flow of $42.7M. Top institutional holders of AMPH by reported 13-F value include BlackRock, DIMENSIONAL FUND ADVISORS, STATE STREET, based on the most recent SEC filings. AMPH trades on the Nasdaq exchange and files with the SEC under CIK 1297184. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Amphastar Pharmaceuticals, Inc. directly from SEC EDGAR. Amphastar Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 40 and 81 since 2021, currently 50.5 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$183.9M
Net Income
Q2 2026
$30.3M
Free Cash Flow
Q2 2026
$42.7M
ROIC
Q2 2026
11.5%
D/E Ratio
Q2 2026
0.80
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-1.7% YoYNet Income
-38.5% YoYOperating Income
-31.7% YoYEPS (Diluted)
-33.7% YoYTotal Assets
+3.3% YoYTotal Debt
+1.2% YoYOp. Cash Flow
-26.8% YoYFree Cash Flow
-29.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $719.9M -1.7% | $732.0M +13.6% | $644.4M +29.1% | $499.0M +14.0% | $437.8M +25.1% | $349.8M |
| Net Income | $98.1M -38.5% | $159.5M +16.0% | $137.5M +50.5% | $91.4M +47.1% | $62.1M +4327.4% | $1.4M |
| Operating Income | $140.4M -31.7% | $205.4M +4.3% | $197.0M +83.2% | $107.5M +53.8% | $69.9M +538.0% | $11.0M |
| EPS (Diluted) | $2.03 -33.7% | $3.06 +17.7% | $2.60 +49.4% | $1.74 +39.2% | $1.25 +4066.7% | $0.03 |
| Total Assets | $1.63B +3.3% | $1.58B +4.3% | $1.51B +103.9% | $742.0M +10.5% | $671.5M +6.4% | $631.2M |
| Total Debt | $621.3M +1.2% | $613.8M +1.7% | $603.6M +657.5% | $79.7M -0.9% | $80.4M +38.2% | $58.2M |
| Operating Cash Flow | $156.1M -26.8% | $213.4M +16.3% | $183.5M +105.8% | $89.2M -9.0% | $98.0M +71.1% | $57.3M |
| Free Cash Flow | $121.2M -29.7% | $172.3M +18.6% | $145.3M +123.1% | $65.1M -7.6% | $70.5M +201.3% | $23.4M |
Get alerted when AMPH's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Amphastar Pharmaceuticals, Inc. including:
Top Institutional Holders of AMPH
BlackRock, Inc.
$105.4M5,224,934 shDIMENSIONAL FUND ADVISORS LP
$46.5M2,305,107 shSTATE STREET CORP
$33.1M1,642,126 shVANGUARD CAPITAL MANAGEMENT LLC
$29.9M1,481,952 shAMERICAN CENTURY COMPANIES INC
$23.7M1,176,626 shMARSHALL WACE, LLP
$21.5M1,066,322 shGEODE CAPITAL MANAGEMENT, LLC
$19.6M969,840 shFULLER & THALER ASSET MANAGEMENT, INC.
$19.2M949,238 shD. E. Shaw & Co., Inc.
$17.9M887,048 shVANGUARD PORTFOLIO MANAGEMENT LLC
$16.3M809,568 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $105.4M | 5,224,934 |
| DIMENSIONAL FUND ADVISORS LP | $46.5M | 2,305,107 |
| STATE STREET CORP | $33.1M | 1,642,126 |
| VANGUARD CAPITAL MANAGEMENT LLC | $29.9M | 1,481,952 |
| AMERICAN CENTURY COMPANIES INC | $23.7M | 1,176,626 |
| MARSHALL WACE, LLP | $21.5M | 1,066,322 |
| GEODE CAPITAL MANAGEMENT, LLC | $19.6M | 969,840 |
| FULLER & THALER ASSET MANAGEMENT, INC. | $19.2M | 949,238 |
| D. E. Shaw & Co., Inc. | $17.9M | 887,048 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $16.3M | 809,568 |
Companies Similar to AMPH
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Pacira BioSciences, Inc.
CONMED Corp
COLLEGIUM PHARMACEUTICAL, INC
Pediatrix Medical Group, Inc.
PUMA BIOTECHNOLOGY, INC.
HAEMONETICS CORP
Embecta Corp.
Prestige Consumer Healthcare Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put AMPH on your watchlist
Track score changes the day Amphastar Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AMPH a good stock to buy?
13F Pro's AI-powered analysis of Amphastar Pharmaceuticals, Inc. (AMPH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AMPH are available on the AMPH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AMPH is classified as a small company.
Which hedge funds own AMPH?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AMPH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Amphastar Pharmaceuticals, Inc.'s investment landscape.